Immuneering (IMRX) Change in Receivables (2020 - 2023)
Immuneering (IMRX) posted quarterly Change in Receivables of -$1046.0 for Q2 2023, up 98.97% year-over-year from -$525.72 in Q2 2022, and up 90.8% quarter-over-quarter from -$11371.0 in Q1 2023.
Powered by 
Analysis
Immuneering (IMRX) Change in Receivables (2020 - 2023) Analysis & Trends
Immuneering's Change in Receivables history runs 4 years deep, the most recent figure standing at -$1046.0 for Q2 2023.
- In Q2 2023, Change in Receivables rose 98.97% year-over-year to -$1046.0; the TTM figure through Mar 2024 stood at -$1046.0 (up 99.62% YoY), while the FY2023 annual figure was -$12417.0, up 94.69% from the prior year.
- Change in Receivables for Q2 2023 stood at -$1046.0, up from -$11371.0 in the prior quarter.
- The five-year high for Change in Receivables was $278185.0 in Q3 2020, with the low at -$250978.0 in Q4 2021.
- The 4-year median for Change in Receivables is -$17550.5 (2021), against an average of -$27133.6.
- Peak annual rise in Change in Receivables reached 535.73% in 2022, while the deepest fall reached 3847.7% in 2022.
- Immuneering's Change in Receivables stood at -$78035.0 in 2020, then plunged by 221.62% to -$250978.0 in 2021, then jumped by 76.98% to -$57763.0 in 2022, then surged by 98.19% to -$1046.0 in 2023.
- Business Quant data shows IMRX's Change in Receivables at -$1046.0 in Q2 2023, -$11371.0 in Q1 2023, and -$57763.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Immuneering | 313.13 Mn | 313.13 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -1,046.00 |
| Mar 31, 2023 | -11,371.00 |
| Dec 31, 2022 | -57,763.00 |
| Sep 30, 2022 | -108,245.00 |
| Jun 30, 2022 | -101,188.00 |
| Mar 31, 2022 | 33,573.00 |
| Dec 31, 2021 | -250,978.00 |
| Sep 30, 2021 | -23,730.00 |
| Jun 30, 2021 | 2,700.00 |
| Mar 31, 2021 | -7,705.00 |
| Dec 31, 2020 | -78,035.00 |
| Sep 30, 2020 | 278,185.00 |